Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 7/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.54 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.41 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.41 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.41 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | SCARB1 | Q8WTV0 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2025854 | 1.00 | HTR6 (0.54) | HTR6HRH1EGFRIGF1RFLT4 | |
| SCHEMBL2024144 | 0.99 | HRH1 (0.55) | HTR6HRH1EGFRIGF1RFLT4 | |
| SCHEMBL3150253 | 0.90 | HTR6 (0.57) | HTR6HRH1EGFRIGF1RFLT4 | |
| Hydrochloric Acid SCHEMBL17592674 | 0.88 | HTR6 (0.54) | HTR6HRH1EGFRIGF1RFLT4 | |
| SCHEMBL19015842 | 0.87 | HRH1 (0.55) | HTR6HRH1SCARB1CNR2AR | |
| SCHEMBL16493815 | 0.87 | HRH1 (0.43) | HTR6HRH1EGFRIGF1RFLT4 | |
| SCHEMBL14218080 | 0.84 | EGFR (0.42) | HTR6HRH1EGFRIGF1RFLT4 | |
| SCHEMBL2019197 | 0.83 | HRH1 (0.40) | HTR6HRH1SCARB1 | |
| SCHEMBL12579014 | 0.83 | HRH1 (0.40) | HTR6HRH1SCARB1 | |
| SCHEMBL2024874 | 0.82 | HRH1 (0.48) | HTR6HRH1SCARB1CNR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148694-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2024-05-09 | — | — | US | disclosed |
| CN-113651797-A | Treatment of symptoms associated with castration therapy | 伊莱利利公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113521068-A | Treatment of symptoms associated with castration therapy | 伊莱利利公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200390744-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2020-12-17 | — | — | US | disclosed |
| US-10799478-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-10-13 | — | — | US | disclosed |
| US-10758515-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3191094-B1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | LILLY CO ELI (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190111039-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3375444-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20170172992-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY | 2017-06-22 | — | — | US | disclosed |
| EP-2094658-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148694-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HTR6 634/4885HRH1 2142/4885EGFR 720/4885 |
| US-20190111039-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HTR6 634/4885HRH1 2142/4885EGFR 720/4885 |
| US-20200390744-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HTR6 634/4885HRH1 2142/4885EGFR 720/4885 |
| US-20170172992-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, AR | HTR6 895/4885HRH1 2079/4885EGFR 400/4885 |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | HTR6 251/4885HRH1 1313/4885EGFR 1267/4885 |
| US-10758515-B2 | Treatment of androgen deprivation therapy associated symptoms | NR5A1, CYP17A1, SHBG | HTR6 759/4885HRH1 1830/4885EGFR 679/4885 |
| US-10799478-B2 | Treatment of androgen deprivation therapy associated symptoms | NR5A1, CYP17A1, SHBG | HTR6 634/4885HRH1 2142/4885EGFR 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.